Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer
This study has been completed.
Information provided by (Responsible Party):
First received: June 15, 2007
Last updated: January 14, 2016
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||October 2011|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS, Hotte SJ. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann Oncol. 2016 Jun;27(6):1116-22. doi: 10.1093/annonc/mdw068. Epub 2016 Feb 18.